ArticleCureus2026
Hemoglobin Response to a Low-Iron Dose in Infantile Anemia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIron-deficiency anemia (IDA) is common during infancy, especially among infants exclusively breastfed after six months of age. The recommended therapeutic iron dose is 3-6 mg/kg/day; however, excessive iron load can be harmful due to alteration of the gut microbiome and oxidative stress to the developing organs. Lower doses of iron have shown efficacy in treating IDA in adults. This retrospective study evaluated the hemoglobin (Hb) response to a lower iron dose in infantile anemia.
methodsDuring health checkups for 9- to 10-month-old infants, anemia screening was conducted for those who were exclusively breastfed. Clinical parameters, including birth date, gestational age, birth weight, and body weight at the start of iron supplementation, were recorded. Venous blood samples were collected for a complete blood count (CBC). Infants with either Hb levels below 11.0 g/dL or mean corpuscular volume below 70 fL received a therapeutic iron trial. From March 2016 to November 2018, a fixed dose of elemental iron (soluble ferric pyrophosphate) 15 mg/day was administered (reference group), and from November 2018 to December 2023, a dose of 1 mg/kg/day was given (low-dose group). CBC measurements were repeated after four weeks, and Hb responses were compared between the two regimens.
resultsA total of 26 children in the reference group and 27 in the low-dose group were finally analyzed. The fixed 15 mg/day dose in the reference group corresponded to 1.8 (1.6-1.9) (median (interquartile range) mg/kg/day). Baseline clinical variables showed no statistically significant differences between the two groups. The median Hb increase was 1.6 g/dL and 1.5 g/dL, with 69% (18/26) and 70% (19/27) of children achieving an Hb level ≥ 1 g/dL, in the reference and low-dose groups, respectively. All 15 children (15/27, 56%) in the low-dose group, who met the new WHO anemia definition at the age of 6-23 months of Hb < 10.5 g/dL, had an Hb response ≥ 1.0 g/dL, with a median Hb response of 2.2 g/dL.
conclusionAn iron dose of 1 mg/kg/day was as effective as 15 mg/day (median: 1.8 mg/kg/day) in the Hb response. In all children with Hb < 10.5 g/dL, the iron dose of 1 mg/kg/day showed substantial Hb responses. These findings suggest that therapeutic iron doses lower than conventional recommendations may be effective for managing IDA and mitigating the harmful effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.